Introduction
============

With the isolation and characteristication of cancer stem cells (CSCs) from different solid tumors, CSCs are regarded as a subset of cells that have the ability of self-renewal and generation of heterogeneous tumor cells. However, mechanisms underlying CSC self-renewal regulation remain elusive [@B1]. While pluripotent genes of normal stem cells (NSCs) have been shown to be capable of regulating the self-renewal of CSCs, including *Oct4* and *Nanog*, differences exist between the NSCs and CSCs in self-renewal regulation [@B2]-[@B4]. A body of studies have showed the promoting effect of Epithelial-mesenchymal transition (EMT) on the stemness of CSCs [@B5]-[@B8]. EMT is an important step in embryonic development in which epithelial cells are polarized into stromal cells with stronger motility, which enables cells to move long distances into the inner layer of the embryo and participate in the formation of internal organs [@B9]. Similarly, EMT also plays a role in wound healing and in the development of some diseases, such as fibrosis. In cancers, EMT is required for the initiation of metastasis. Alberto Martin and Amparo Cano suggested that EMT is not only associated with tumor metastasis, but also with the acquisition of stem cells [@B10], [@B11].

*Twist1*, *Twist2*, *Snai1* and *Zeb1* can induce the stemness properties of CSCs by promoting EMT process [@B11]-[@B13]. Alain Puisieux et al. showed that Twist1 maintains self-renewal of CSCs by directly activating *BMI1*, which encodes a comb protein and inhibits INK4A/ARF [@B9]. *Zeb1* could activate the transcription of stemness related genes *Bmi1*, *Sox2*, *Klf4* and *Sox9* by inhibiting their miRNA regulator - the miR-200 family [@B9], [@B14]. *Twist2* could regulate the self-renewal of CSCs through the *Twist2*-CD24-STAT3-*Nanog* pathway in hepatocellular carcinoma which is a highly conserved transcription factor of helix-loop-helix structure and similar to *Twist1* [@B6]. In this study, we identified the asymmetric division gene *Neurl2*, as a new gene target of *Twist2* that mediates the regulation of CSC self-renewal.

Stem cell renewal can be achieved by symmetrical division, as well as asymmetric divisions. Through these two types of cell division, stem cells can produce differentiated cells needed for growth and development, and at the same time maintain a stable number of undifferentiated stem cells for the maintenance of stemness [@B15]. The balance between symmetrically dividing stem cells and asymmetrically dividing stem cells is critical to tissue homeostasis, which is broken in cancers [@B16]. Costa G et al. conducted *in vivo* experiments in zebrafish lead to the hypothesis that asymmetrical division plays a similar role in the development and progression of tumors [@B17].

In this study, we elucidate that *Twis2* can regulate the self-renewal of lung CSCs both *in vitro* and *in vivo*, through transcriptional inactivation of *Neurl2*, a asymmetric division gene of normal stem cells. As importantly, the interaction between *Twist2* and *Neurl2* is clinically relevant. *Neurl2* emerges as a potential marker for lung cancer prognosis. In summary, our research provides a new insight for mechanism under the self-renew regulation of CSCs by EMT.

Results
=======

The establishment and characterization of mouse Lewis lung cancer stem cell lines
---------------------------------------------------------------------------------

The mouse Lewis lung cancer stem cell line LLC-SE was obtained by selecting floating spheroidal cells from the culture of Lewis lung cancer parental cells (LLC-P) (Figure [1](#F1){ref-type="fig"}A). The enhancement in the stemness of LLP-SE cells was confirmed by elevated expression of stemness genes (*Bmil*, *Klf4* and *Nanog*) (Figure [1](#F1){ref-type="fig"}B) and the increased spheroid formation rate and signle cell cloning rate (Figures [1](#F1){ref-type="fig"}C and D). *In vivo*, subcutaneous transplantation of 10^3^ LLC-SE cells to the hinder legs of nude mice resulted in faster tumor growth and larger tumor burden compared to tumors derived from 10^3^ LLC-P cells (Figure [1](#F1){ref-type="fig"}E(i) and (ii)). Further, orthotopic implantation of LLC-SE cells on the left lung in the syngeneic C57 mice showed more robust orthotopic tumor growth and more aggressive course of tumor progression than the LLC-P cells (Figure [1](#F1){ref-type="fig"}F(i) and (ii)). Collectively, these *in vitro* and *in vivo* observations indicate that LLC-SE cells exhibit enhanced stem cell properties and augmented tumorigeneicity.

Twist2 regualtes the stemness of LLC-SE
---------------------------------------

EMT transcript factors (TFs) are shown to promote the stemness of cancer stem cells (CSCs). Thus, the expression of 11 EMT TFs (*Zeb1, Zeb2, Snail1, Snail2, Snail3, Twist1, Twist2, E47, FOXC2, GSC1 and GSC2*) were measured by qPCR in LLC-SE and LLC-P, among which *Zeb1, Zeb2, Snail1, Twist1, Twist2 and E47, FOXC2* were higher in LLC-SE than in LLC-P (Figure [2](#F2){ref-type="fig"}A). The expression of *Twist2* showed the most significant difference between LLC-SE and LLC-P in all of the EMT TFs we assayed. Therefore, we focused the rest of the study on characterizing the role of *Twist2* in regulating the stemness of lung cancer using the LLC-SE model. Interference of *Twist2* expression by lentivirus effectively inhibited its expression, confirmed by qPCR and WB (Figure [2](#F2){ref-type="fig"}B(i) and 2B(ii)). Upon *Twist2* interference, spheroid formation and single cloning rate were significantly reduced (Figure [2](#F2){ref-type="fig"}C and figure [2](#F2){ref-type="fig"}D), indicating hindered stemness. *In vivo*, subcutaneous transplantation of 10^4^ LLC-SE-sh-twist2 in which Twist2 was targeted lead to inhibition of tumor growth compared to LLC-SE-sh-NC control tumors \[Figure [2](#F2){ref-type="fig"}E(i) and 2E(ii)\]. These observations indicate that Twist2 regulate the stemness of LLC-SE.

Neulr2 - the asymmetric division gene mediates Twist2 regualtion of stemness in LLC-SE
--------------------------------------------------------------------------------------

The proportion and balance between symmetrically dividing stem cells (SD) and asymmetrically dividing (ASD) stem cells that are tightly controlled and regulated in normal stem cells are broken in cancers. However, mechanisms regulating SD and ASD in CSCs remain largely unknown. In our previous study, the LLC-SD and LLC-ASD were derived from the LLC-SE and the expression of EMT TFs was higher in LLC-SD cells than that in LLC-ASD cells [@B14], [@B18]. SD and ASD ratio were detected by BrdU labeling (Figure [3](#F3){ref-type="fig"}A, 3B(i) and 3B(ii)). We assayed the expression of a set of known genes that regulate the asymmetric division of normal stem cells including *Prox1, Neurl1a, Neurl2, and LIgl1*. All displayed higher expression in LLC-ASD cells than in LLC-SD cells (Figure [3](#F3){ref-type="fig"}C). In order to explore the relationship between *Twist2* and asymmetric division related genes, the expression of *Prox1*, *Prox2*, *Neul1a*, *Neurl2* and *LIgl1* were detected after *Twist2* knockdown in LLC-SE cells. Inhibition of *Twist2* in LLC-SE cells lead to the upregulation of this panel of asymmetric division genes (Figure [3](#F3){ref-type="fig"}D), exhibiting an inverse relationship. *Twist2* functions often as a transcriptional inhibiting factor. We thus hypothesized that *Twist2* could regulate the stemess of LLC-SE by inhibiting at least one of these asymmetric division genes. We analyzed probable *Twist2* binding sites in *Prox1, Neul1a*, *Neurl2* and *LIgl1* promoter region predicted by JASPAR database (Figure [3](#F3){ref-type="fig"}E). ChIP assay was conducted to identify direct transcriptional targeting of Twist2. We found that *Twist2* could bind to the *Neurl2* promoter region (Figure [3](#F3){ref-type="fig"}F(i) and 3F(ii)), indicative of direct transcriptional inactivation of *Neural2* by *Twist2* in LLC-SE.

The analysis of the relationship between Twist2 and Neurl2 in clinical TCGA data
--------------------------------------------------------------------------------

In order to explore the clinical relevance of *Twist2-Neurl2*, the expression of *Twsit2* and *Neurl2* were analysed in T1+T2 group and T3+T4 group according to human lung adenocarcinoma TMN classification. The expression of *Twsit2* was higher in T1+T2 than T3+T4 and it was opposite for the *Neurl2* (Figure [4](#F4){ref-type="fig"}A(i) and 4(ii)). The analysis of the correlation of *Twsit2* and *Neurl2* revealed a close correlation in human lung adenocarcinoma (Figure [4](#F4){ref-type="fig"}B). At last, the surviving curve of *Twsit2* and *Neurl2* were also analysed through OncoLnc. Lower level of Twist2 and higher level of Neurl2 conferred higher survival rate (Figure [4](#F4){ref-type="fig"}C). These results suggest that *Twsit2* may promote lung CSC self-renewal by inhibiting Neurl2 in human lung adenocarcinoma, and Neurl2 may be explored as a new marker for lung cancer prognosis.

Discussion
==========

Targeting cancer stem cells (CSCs) is an appealing approach for the cure of cancer [@B19]-[@B21]. The ability of CSCs to maintain self-renew as well as to undergo differentiation - though not to completion, bears resemblance to normal stem cells (NSCs). However, mechanisms underlying CSC self-renewal have been largely unknown. In this study, by using the LLC-SE CSC model we developed from the LLC-P model, we characterized the importance of EMT TF *Twist2* in regulating the stemness of LLC-SE (Figure [2](#F2){ref-type="fig"}). Our findings in the adenomacarcinoma of the lung model are consistent with the literature report of *Twist2* on regulating self-renewal of CSCs in the liver and the breast cancer [@B6], [@B22]. More importantly, we provided a new mechanism that underlies *Twist2* regulation of stemness, i.e, the direct *Twist2*-*Neurl2* transcriptional interaction (Figure [3](#F3){ref-type="fig"}F). The clinical relevance of *Twist2*-*Neurl2* interaction was supported by the analysis of TCGA dataset, showing the potential of Neurl2 as a favorable prognostic marker for lung cancer (Figure [4](#F4){ref-type="fig"}).

Prior to this study, the role of *Twist2* in lung cancer progression was explored in the context of EMT [@B9]. Its role in regulating lung CSC self-renewal has not been studied in lung cancer. In some recent reports, *Twist2* was reported to regulate the stemness of hepatocellular carcinoma through CD24-STAT3-Nanog pathway [@B6]. *Twist2* could increase the CD44^high^/CD24^low^ CSC sub-population content in breast cancer [@B22]. In our study, the conventional stemness makers of normal stem cells (*Oct4*, *Sox2*) and lung CSCs CD133, CD44 and ALDH1 were not decreased after *Twist2* knockdown (data not shown). Other studies also reported the unaltered expression of stenmness markers by EMT TFs [@B23]. In our previous study, we showed that *Zeb1*, another EMT TF, could regulate the symmetric division of mouse Lewis lung carcinoma stem cells through *Numb* mediated by miR-31[@B14]. Here, we provided an alternative mechanism CSC stemness regulation by *Twist2* through its transcriptional inactivation of asymmetric geen *Neurl2*. Thus, EMT TFs can elicit robust regulation of lung CSC stemness by augmenting SD and inhibiting ASD division.

Symmetric division (SD) and asymmetric division (ASD) are unique forms of cell division that are essential for the maintenance of stemness of normal stem cells as well as cancer stem cells[@B15]. Recent study showed that some EMT TFs could regulate the self-renew of CSCs through targeting asymmetric division in colon cancer[@B24]-[@B26]. In our previous, SD and ASD cell lines were obtained from the LLC-SE in which the expression of EMT TFs were higher in SD than ASD, and the the relevance of *Twist2* to ASD was confirmed by *Twist2* knockdown in LLC-SE[@B14], [@B18]. *Neurl2* was shown to underly *Twist2* regulation of neurl cells differentiation [@B27]. Our study demonstrates that the transcriptional interaction between Twist2 and Neurl2 in normal stem cells also functions in lung CSCs. Moreover, we provided the first clinical evidence showing the clinical relevance of the interaction between *Twist2* and *Neurl2*, and the potential of exploring *Neurl2* as a favorable prognostic marker for human lung cancer.

In summary, our study indicated that EMT TF *Twist2* can regulate the stemness of lung CSCs by transcriptional inactivation of the asymmetric division factor *Neurl2*.

Materials and methods
=====================

Cell culture
------------

The mouse Lewis lung carcinoma parental cell line (LLC-P) was purchased from the cell bank of the Shanghai Institute of life sciences, Chinese Academy of Sciences. LLC-P cells were cultured with DMEM culture medium contained 1% Amphotericin B, 1% penicillin-streptomycin and 10% FBS. The Lewis Lung Carcinoma-Spheroid Enrichment cells (LLC-SE) and the Lewis Lung carcinoma-Symmetric Division (LLC-SD) cells were cultured in the DMEM culture medium with 2% B27, 1% Amphotericin B and 1% penicillin-streptomycin. And the LLC-ASD cells were cultured in this culture medium containing DMEM ,1% Amphotericin B, 1% penicillin-streptomycin and 5% FBS. All cells were kept in the incubator, with 5% CO~2~ and constant humidity and at 37℃.

Reverse Transcription Polymerase Chain Reaction (RT-PCR)
--------------------------------------------------------

Total RNAs were isolated with Trizol agent. In brief, 1mL Trizol agent were added into the EP tube containing cells, incubated on the ice for 10 minutes, followed addition of 200 uL chloroform and oscillation. Thereafter, the mixture was centrifuged in 4℃ for 15 minutes followed by addition of Isoamyl alcohol and incubation on the ice for 10 minutes. At last, the mixture was centrifuged in 4℃ for 10 minutes followed addition of 70% ice-cold ethanol and preceded with another centrifugation in 4℃ centrifuge for 10 minutes. The pellets were dissolved using 20-30 ul DEPC water. RT-PCR was conducted using PrimeScript RT Master Mix (Takara) according to the manufacturer\'s instructions.

Real-time Quantitative PCR
--------------------------

The reaction system of QPCR was 10µL, containing 5µL mastermix agent, 0.8µL Cdna, 0.8µL primer and 3.4µL DEPC water. Triplicates were set up for every sample. PCR was conducted according to the manufacturer\'s instructions. The sequences of PCR primers are listed in **Table [1](#T1){ref-type="table"}.**

Western Blot
------------

12% of resulving gel and 6% of condensing gel were used in this study. The voltage of electrophoresis was 120V while the current for member transfer was 350 mA. After transfer, the membrane was blocked with 5% of BSA, followed by incubation with the primary antibody (11752-1-AP, Proteintech) at 4℃ for 12h and completed with incubation with the secondary antibody (SA00001-2, Proteintech) at room temperature for 1 hour. The results were acquired using automatic analysis system of electrophoresis gel imaging.

Subcutaneous tumor transplantation in nude mice
-----------------------------------------------

BALB/cA-nude mice were purchased from Beijing Hua Gao Kang Bio Polytron Technologies Inc and were examined by the Institute of medical laboratory animal research, Chinese Academy of Medical Sciences. 10^3^ or 10^4^ cells were injected to each side of the hinder leg of each mouse. After tumor cell transplantation, tumor volume was measured every two days between Day 11 day and Day 23 and was plotted.

Orthotopic tumor cell transplantation in C57/BL6 mice
-----------------------------------------------------

C57/BL6 mice were purchased from the Laboratory Animal Center of Chongqing medical university, and the protocol was approved by the animal ethics committee. After being anaesthetized with 1% pentobarbital, the left chest was exposed and the skin was disinfected with 75% alcohol. A longitudinal incision was made at the cardiopulmonary junction, 1x10^5^ cells were injected. 3 weeks later, the extent of metastasis to the left lung, the right lung and the thymus as well as to the walls of the chest were examined and recorded.

Immunofluorescence
------------------

The cells were treated with BrdU for at least seven days, followed by BrdU withdrawal for at least two days. Cells were harvested, fixed with ice-cold 70% ethanol for 30 minutes, and ttreated with hydrochloric acid for 1 hour. Cells were washed with PBS for three times, the slides were blocked with 10% BSA solution in the shaker at 37℃ for 1 hour. Thereafter, the cells were incubated with the first antibody (anti-BrdU, Millipore) at 4℃ for 12 hour with gentle agitation, followed by incubation with the secondary antibody (Proteintech) at 37℃ for 1 hour. Images were taken by OLYMPUS inverted fluorescence microscope.

Chromatin immunoprecipitation (ChIP) assay
------------------------------------------

The ChIP assay was performed with the Chromatin immunoprecipitation (ChIP) Assay Kit of Beyotime Biotechnology according to manufacturer\'s instructions. Firstly, cells were cross-linked in 300 µl formaldehyde for 10 min at room temperature and the reaction was stopped by incubation with 500 µl 2.5mol/L Glycine solution at room temperature for 5 min. Then, the mixture was poured out and the PBS with 10x PMSF buffer was added into the precipitation and centrifuged at 2000g for 4 min. Thereafter, 1 ml SDS/lysis buffer was added into the precipitation and the mixture was broken via sonication, followed by incubation with the first antibody (Abcam) at 4℃ for 12 hour. Then 60ul protein A Agarose were added and incubated with gentle oscillation at 4℃. The mixture was then centrifuged and washed with Low salt solution, high salt solution and LiCl solution sequnetially. Finally, the precipitates were washed twice wth TE buffer. DNA was extracted using a Extraction Kit from Tiangen company. At last, QPCR assay was performed using the freshly extracted DNA.

Lentivirus packaging and infection
----------------------------------

Stable knockdown of Twist2 was achieved with infection of cells with pLL3.7 in the presence of 8 μg/mlpolybrene (Genepharma, China) for 12 hours, and the medium was changed at 72 hours post infection.

TCGA Data Analysis
------------------

The mRNA expression of *Twist2* in lung adenocarcinoma was evaluated by TCGA Research Network (<http://cancergenome.nih.gov>). To analyze the survival of patients with lung adenocarcinoma, patient samples were analysed by OncoLnc (<http://www.oncolnc.org>).

Statistical analysis
--------------------

Data were analyzed by one-way analysis of variance using GraphPad Prism software and presented as mean ± SD or SEM. Differences were considered statistically significant when P \< 0.05.
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![**The establishment and identification of mouse Lewis lung cancer stem cell lines. A.**The morphology of LLC-P cells and LLC-SE cells, bar=120um. **B.** the analysis of mRNA expression of *Bmi*, *Nanog* and *Klf4* in LLC-SE and LLC-P cells, the tata-Box binding protein gene (Tbp) was used as a reference control. **C.** the analysis of spheroid formation rate of 1000 cells in 6 well plate in LLC-SE cells and LLC-P cells. **D.** the analysis of spheroid formation rate of single cell in 96 well plate in LLC-SE cells and LLC-P cells. **E. (i)** and **(ii)** tumor formation in nude mice after injection. **F. (i)** and **(ii)** the procedure of orthotopic tumor transplantation in C57BL/6 mice.](jcav10p3381g001){#F1}

![***Twist2* enhances the stemness properties of LLC-SE cells. A.** mRNA expression analysis of 11 Epithelial-Mesenchymal Transition (EMT) factors in the LLC-SE and LLC-P cells, the tata-Box binding protein gene (Tbp) was used as a reference control. **B.(i) and (ii)** verification of the efficiency of sh-mediated knockdown of *Twist2* at mRNA and protein levels. **C.** the analysis of spheroid formation rate of 1000 cells in 6-well plate in LLC-SE-sh-NC cells and LLC-SE-sh-twist2 cells. **D.** the analysis of spheroid formation rate of single cell in 96 well plate in LLC-SE-sh-NC cells and LLC-SE-sh-twist2 cells. **E.(i) and (ii)** tumor formation in nude mice after injection derived from LLC-SE-sh-NC and LLC-SE-sh-twist2.](jcav10p3381g002){#F2}

![**Twist2 regulates the stemness of LLC-SE via regulating the expression of asymmetric division related genes. A.** The morphology of LLC-SE, LLC-SD and LLC-ASD cells, bar=120um. **B.(i)** Analysis of symmetric and asymmetric segregation of BrdU-labeled DNA during mitosis in anaphase LLC-SD and LLC-ASD, bar=120um.**(ii)** Quantification of SD and ASD cells in 100 dividing anaphase LLC-SD and LLC-ASD, respectively. **C.** the analysis of mRNA expression of asymmetric division genes in the LLC-SD and LLC-ASD, the tata-Box binding protein gene (Tbp) was used as a reference control. **D.** the analysis of mRNA expression of asymmetric division genes in LLC-SE-sh-NC and LLC-SE-sh-twist2, Tbp was used as a reference control. **E.** potential twist2 binding sites on the promoter regions of asymmetric division genes predicted through JASPAR database. **G. (i)** ChIP assay for determining the nature of interaction between Twist2 and asymmetric division genes. **(ii)** ChIP assay for determining the nature of interaction between *Twist2* and *Neurl2*.](jcav10p3381g003){#F3}

![**The analysis of correlation between Twist2 and Neurl2 in clinical TCGA data. A. (i) and (ii).** the analysis of mRNA expression of *Twist2* and *Neurl2* in human lung adenocarcinoma from TCGA database, T1, T2, T3 and T4 were the TMN classification, n was the number of human lung adenocarcinoma samples. **B.** the analysis of correlation between *Twist2* and *Neurl2* in the human lung adenocarcinoma, n was the number of human lung adenocarcinoma samples. **C. (i) and (ii)** the survival curve of human lung adenocarcinoma patients were classified as the expression of *Twist2* and *Neurl2*.](jcav10p3381g004){#F4}

###### 

PCR Primer Sequence

  Gene name   Forward primers           Reverse primers
  ----------- ------------------------- -------------------------
  *Tbp*       CCGTGAATCTTGGCTGTAAAC     CAGTTGTCCGTGGCTCTCTT
  *Bmi1*      ATCCCCACTTAATGTGTGTCCT    CTTGCTGGTCTCCAAGTA ACG
  *Nanog*     TTAGAAGCGTGGGTCTTGGT      CCCTCA AACTCCTGGTCCTT
  *Klf4*      GGACCACCTTGCCTTACACA      GACTTGCTGGGAACTTGACC
  *Zeb1*      CTCCCAGTCAGCCACCTTTA      TAACTCCATCCAGCGGTAGG
  *Zeb2*      TTTCCTGCCCTCTTTGTAGC      CCTTGGGTTAGCATTTGGTG
  *Snail1*    CACACGCTGCCTTGTGTCT       GGTCAGCAA AAGCACGGTT
  *Snail2*    TGGTCAAGAAACATTTCAACGCC   GGTGAGGATCTCTGGTTTTGGTA
  *Snail3*    ACAGCGAAC TGG ACA CACAC   GGGTAAAGGAGAGTGGAG TGG
  *Twist1*    GGACAAGCTGAGCAAGAT TCA    CGGAGA AGGCGT AGCTGAG
  *Twist2*    GTCTCAGCTACGCCTTCTCC      AGATGTGCAGGT GGGTCCT
  *E47E2a*    GCAAACGAAGGCAGAGTAGG      TGGTCAAGAGACACCTCA AGC
  *Foxc2*     AACCCAACAGCAAACTTCCC      GCGTAGCTCGATAGGGCAG
  *Gsc1*      AACGCCGAGAAGTGGAACAAG     CCGAGTCCAAATCGCTTT TACC
  *Gsc2*      CGTGGAGGTCTGGTTCAAG       CGGACAGCATCA ACA ACTCT
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